Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00NZL
|
|||
| Former ID |
DNCL002326
|
|||
| Drug Name |
LY2603618
|
|||
| Synonyms |
LY2603618; Rabusertib; 911222-45-2; LY 2603618; LY-2603618; UNII-3S9L1NU6U7; 3S9L1NU6U7; IC-83; ly2603618 IC-83; (S)-1-(5-bromo-4-methyl-2-(morpholin-2-ylmethoxy)phenyl)-3-(5-methylpyrazin-2-yl)urea; n-(5-bromo-4-methyl-2-((2s)-2-morpholinylmethoxy)phenyl)-n'-(5-methyl-2-pyrazinyl)urea; LY2603618 (IC-83); Rabusertib [USAN:INN]; 3-(5-Bromo-4-methyl-2-[(2s)-morpholin-2-ylmethoxy]phenyl)-1-(5-methylpyrazin-2-yl)urea; N-[5-Bromo-4-methyl-2-[(2S)-2-morpholinylmethoxy)phenyl]-N'-(5-methyl-2-pyrazinyl)urea
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Pancreatic cancer [ICD-11: 2C10] | Phase 2 | [1], [2] | |
| Company |
Eli Lilly
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C18H22BrN5O3
|
|||
| Canonical SMILES |
CC1=CC(=C(C=C1Br)NC(=O)NC2=NC=C(N=C2)C)OCC3CNCCO3
|
|||
| InChI |
1S/C18H22BrN5O3/c1-11-5-16(27-10-13-8-20-3-4-26-13)15(6-14(11)19)23-18(25)24-17-9-21-12(2)7-22-17/h5-7,9,13,20H,3-4,8,10H2,1-2H3,(H2,22,23,24,25)/t13-/m0/s1
|
|||
| InChIKey |
SYYBDNPGDKKJDU-ZDUSSCGKSA-N
|
|||
| CAS Number |
CAS 911222-45-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
17399809, 24481461, 36453169, 77268992, 136340188, 136349524, 136367655, 136367891, 140472988, 144116162, 152258593, 160647428, 162011919, 162038076, 162109042, 164023434, 170467345, 172232490, 174007107, 174510191, 174531422, 185969758, 198976853, 223705091, 226644713, 246865050, 249565643, 251963138, 252110175
|
|||
| ChEBI ID |
CHEBI:124917
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7960). | |||
| REF 2 | ClinicalTrials.gov (NCT00988858) A Study of Advanced or Metastatic Non-small Cell Lung Cancer. U.S. National Institutes of Health. | |||
| REF 3 | Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.